logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

BEAUTYFARM MED (02373) spent 376,500 Hong Kong dollars on May 13 to repurchase 19,500 shares.

date
20:03 13/05/2026
avatar
GMT Eight
Beautiful Countryside Medical Health (02373) announced that it repurchased 19,500 shares for HK$37.65 thousand on May 13, 2026.
BEAUTYFARM MED (02373) announced on May 13, 2026, that it will spend 376,500 Hong Kong dollars to repurchase 19,500 shares.
Related Articles
HK Stock
SMART GLOBE (01481): Proposal to Adopt the 2026 Stock Incentive Plan.
China Stock
A-share Announcement Highlights | Shenzhen Honor Electronic (300870.SZ): Rapid growth in data center power business, cooperation with Google on GPU power project established.
HK Stock
AB&B BIO-TECH-B (02627) has initiated phase I and phase II clinical trials of a recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvant).
SMART GLOBE (01481): Proposal to Adopt the 2026 Stock Incentive Plan.
HK Stock
A-share Announcement Highlights | Shenzhen Honor Electronic (300870.SZ): Rapid growth in data center power business, cooperation with Google on GPU power project established.
China Stock
AB&B BIO-TECH-B (02627) has initiated phase I and phase II clinical trials of a recombinant respiratory syncytial virus vaccine (CHO cells) (adjuvant).
HK Stock
RECOMMEND
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
Two Mainland Accounting Firms Approved for H‑Share Audits, Lowering Listing Costs and Deepening Mainland–Hong Kong Market Integration**The Ministry of Finance, the CSRC, and Hong Kong’s Accounting and Financial Reporting Council have approved two additional mainland accounting firms—RSM China and ShineWing—to conduct H‑share audit work, marking the first expansion of the list since 2010.
icon
11/05/2026
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
HKEX Tightens Rules on Auditor Dismissals as Sudden “Audit Firm Switches” Raise Governance Concerns
icon
11/05/2026
The Chip Stock Frenzy Is Still Accelerating
The Chip Stock Frenzy Is Still Accelerating
icon
11/05/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.